Direct-to-Consumer Drug Advertising Rules and GLP-1 Marketing
The U.S. is one of the only countries that allows direct-to-consumer prescription drug advertising, and GLP-1 drugs have become some of its most visible examples.
By the GLP Semaglutide editorial team · Last updated April 10, 2026
The United States and New Zealand are the only two countries that broadly permit direct-to-consumer (DTC) advertising of prescription drugs; most other countries, including EU member states, prohibit or tightly restrict it, which is part of why GLP-1 marketing looks so different across borders.
What FDA rules require
FDA rules for DTC drug ads require a fair balance of risk and benefit information and prohibit false or misleading claims, with the FDA able to issue warning letters for ads that violate these standards.
Telehealth marketing adds a newer layer
Telehealth platforms marketing GLP-1 access have drawn separate FTC scrutiny over advertising claims about ease of access, pricing, and outcomes — a newer regulatory front distinct from traditional pharmaceutical company DTC advertising.
Primary sources